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Abstract
Background: Many neurodegenerative diseases are associated with protein misfolding/aggregation. Treatments
mitigating the effects of such common pathological processes, rather than disease-specific symptoms, therefore
have general therapeutic potential.
Results: Here we report that the anti-epileptic drug ethosuximide rescues the short lifespan and chemosensory
defects exhibited by C. elegans null mutants of dnj-14, the worm orthologue of the DNAJC5 gene mutated in
autosomal-dominant adult-onset neuronal ceroid lipofuscinosis. It also ameliorates the locomotion impairment and
short lifespan of worms expressing a human Tau mutant that causes frontotemporal dementia. Transcriptomic
analysis revealed a highly significant up-regulation of DAF-16/FOXO target genes in response to ethosuximide; and
indeed RNAi knockdown of daf-16 abolished the therapeutic effect of ethosuximide in the worm dnj-14 model.
Importantly, ethosuximide also increased the expression of classical FOXO target genes and reduced protein
aggregation in mammalian neuronal cells.
Conclusions: We have revealed a conserved neuroprotective mechanism of action of ethosuximide from worms to
mammalian neurons. Future experiments in mouse neurodegeneration models will be important to confirm the
repurposing potential of this well-established anti-epileptic drug for treatment of human neurodegenerative
diseases.
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Background
A major challenge in current neurodegeneration research is
the identification of effective therapies. Over recent years,
simple model organisms, such as the nematode worm Cae-
norhabditis elegans, have been increasingly recognised as
powerful systems for revealing the conserved molecular
mechanisms that underlie neurodegeneration [1]. Indeed
various laboratories have developed and characterised a
diverse set of C. elegans models of various human neurode-
generative diseases, including Alzheimer’s [2], Parkinson’s
[3] and polyglutamine expansion diseases [4]. Genetic
screens performed in these models have identified a variety
of genes that can suppress or increase disease progression
and are thus potential therapeutic drug targets. However,
relatively few of these genetic modifiers are common to
more than one disease model, despite the shared feature of
protein misfolding/aggregation [5, 6].
Complementary to its utility for genetic screens, C.
elegans is a useful pharmacological model for testing
potential neuroprotective compounds. Attention has
mainly focused on screening existing FDA-approved
medications rather than novel compounds, as repur-
posing of drugs pre-approved for other indications
obviates the need for early toxicity trials and thus
expedites translation to clinical testing [7, 8]. For ex-
ample, C. elegans Alzheimer’s models expressing human
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Aβ1–42 have identified neuroprotective effects of several
approved compounds, including antibiotic, antidepressant
and antihypertensive drugs [9]. Similarly, dopamine D2 re-
ceptor antagonists have been shown to ameliorate mutant
tau-induced functional defects and reduce aggregation in a
frontotemporal dementia with parkinsonism-17 (FTDP-17)
tauopathy model [10]. A wide variety of other neuroprotec-
tive compounds have also been identified in chemical
screens using worm neurodegeneration models including
spinal muscular atrophy [11], Parkinson’s [12] and
Huntington’s diseases [13].
Most compounds identified in C. elegans chemical
screens to date are effective in only a single neurodegenera-
tive model, suggesting that translational potential may be
disease-specific. However, some compounds, such as res-
veratrol, have been shown to be protective in a range of
worm models and also in mammalian systems [14–18].
This demonstrates that it is possible to identify generally
neuroprotective compounds that alleviate the functional
consequences of protein misfolding common to neurode-
generation. Here we report that ethosuximide, a widely pre-
scribed anti-epileptic drug, improves the phenotypes of
multiple neurodegenerative disease models and we reveal a
conserved action of the drug in modulating DAF-16/FOXO
target gene expression in worms and mammalian neurons.
Results
Ethosuximide ameliorates C. elegans dnj-14 mutant
phenotypes
The rare hereditary human neurodegenerative disease,
autosomal-dominant adult-onset neuronal ceroid lipofus-
cinosis (ANCL), is caused by mutations in the DNAJC5
gene [19–22]. DNAJC5 encodes a neuronal chaperone of
the DnaJ/Hsp40 family of molecular chaperones known as
cysteine string protein (CSP), which prevents the misfold-
ing of presynaptic proteins [23–27]. DNJ-14 is the worm
orthologue of CSP and dnj-14 null mutants are charac-
terised by reduced lifespan and age-dependent sensori-
motor defects and neurodegeneration, similar to CSP
knockout mice [18, 28]. We used this dnj-14 model to
screen for compounds with therapeutic potential for
ANCL and possibly other neurodegenerative diseases, by
testing their ability to extend the short lifespan of dnj-
14(ok237) worms [18]. The anti-epileptic drug, ethosuxi-
mide, was observed to produce a robust and reproducible
lifespan extension in dnj-14(ok237) animals. This effect
was concentration-dependent, with 1 mg/ml ethosuximide
offering the most significant lifespan increase, raising the
mean lifespan of dnj-14(ok237) worms by over 40 %
(Fig. 1a) Over a series of experiments, this optimal con-
centration produced a near-complete rescue of lifespan in
dnj-14 mutants to levels close to that of wild-type N2
worms (Additional file 1: Table S1). At the highest
concentration used (4 mg/ml), ethosuximide produced no
significant increase in lifespan. Notably, none of the con-
centrations used had any significant effect on the lifespan
of wild-type N2 C. elegans (Additional file 2: Figure S1A;
Additional file 1: Table S1). To test if ethosuximide was
also able to rescue the sensory defect in dnj-14 mutants,
we performed a food race assay, which measures the time
taken for animals to move a defined distance to a bacterial
food source (Fig. 1b). As previously observed [18], dnj-14
mutants are severely impaired in this assay. Ethosuximide
significantly improved food sensing activity of dnj-14
mutants, approximately doubling the number of worms
reaching the food within 60 min, although complete res-
cue to wild type levels was not achieved (Fig. 1b). Ethosux-
imide had no stimulatory activity in food race assays using
wild type N2 worms (Fig. 1b), nor did it increase locomo-
tion of dnj-14 or N2 worms in thrashing assays (Additional
file 2: Figure S1B). Therefore the stimulatory action of etho-
suximide in food race assays appears to be due to a specific
effect on the chemosensory defect in dnj-14 mutants rather
than a generic stimulation of movement. Taken together,
these data suggest that ethosuximide is able to ameliorate
the neurotoxicity induced by the loss of the DNJ-14 synap-
tic chaperone protein.
Ethosuximide alleviates phenotypes caused by expression
of human mutant Tau
To determine if ethosuximide had general neuroprotec-
tive activity, we evaluated its effects on a C. elegans fron-
totemporal dementia with parkinsonism-17 (FTDP-17)
tauopathy model [29]. FTDP-17 is one of many human
tauopathies in which characteristic neurofibrillary tan-
gles are formed from hyperphosphorylated Tau. Overex-
pression of human mutant Tau V337M throughout the
C. elegans nervous system causes severe motility defects,
neurodegeneration, short lifespan and accumulation of
insoluble Tau [29]. The highly penetrant and easily ob-
servable motility phenotype of this model is well suited
for assessing drug effects [10]. We observed that etho-
suximide improved the severely uncoordinated pheno-
type of Tau V337M transgenic worms in solution. To
quantify this effect, we performed thrashing assays in
the presence of varying concentrations of ethosuximide.
As shown in Fig. 1c, ethosuximide increased the thrash-
ing frequency of young worms in a dose-dependent
manner, with an optimal concentration of 1-2 mg/ml.
Although this stimulatory effect was highly significant
(P < 0.001) and approximately doubled thrashing rates at
these concentrations, this still represents only a relatively
small increase that is far from a complete rescue to wild
type levels. Nevertheless, the effects were Tau-specific,
because control worms showed wild-type thrashing ac-
tivity that was not increased by ethosuximide (Fig. 1c;
Additional file 2: Figure S1C). Ethosuximide significantly
increased thrashing in young animals (day 1 and 3), but
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its therapeutic activity declined in older animals (Fig. 1d).
To directly test the effect of ethosuximide on longevity,
lifespan assays were performed on ethosuximide treated
Tau V337M and wild type worms and compared with
vehicle-treated controls. Ethosuximide significantly en-
hanced the mean lifespan of Tau V337M worms in a
concentration-dependent manner (Fig. 1e; Additional file
1: Table S1), but had no effect on wild type control
worms (Additional file 2: Figure S1D; Additional file 1:
Table S1). Maximal lifespan extension was seen at 2 mg/
ml, which conferred a 40 % lifespan increase - compar-
able to the longevity effect of ethosuximide seen with
Fig. 1 Ethosuximide increases lifespan and improves sensorimotor function in C. elegans ANCL and frontotemporal dementia models.
a Ethosuximide extends lifespan in dnj-14 mutants. Viability of age-synchronised dnj-14(ok237) animals grown in the presence of the indicated
concentrations of ethosuximide was determined; untreated wild type control N2 worms are shown for comparison (n = 50-55 worms for each
concentration). b Ethosuximide ameliorates the dnj-14 food sensing defect. The time taken to move to a bacterial food source was measured in
wild type N2 and dnj-14(tm3223) strains grown until 5-6 days of age in the presence or absence of ethosuximide (n = 71-80 worms of each strain
per condition). c Ethosuximide increases locomotion in Tau V337M worms, but not control worms. Thrashing in solution was measured in Tau
V337M worms grown until 1 and 3 days of age and assayed in the presence of the indicated concentrations of ethosuximide (for each age group,
n = 120-140 worms for 0 mg/l; n = 38-40 worms for 0.1, 0.2 and 0.5 mg/ml; n = 80-90 worms for 1 and 2 mg/ml;). Identically treated wild type
control CZ1200 worms are shown for comparison (n = 20 worms per concentration). Data are shown as mean ± SEM (***p < 0.001). d Age-
dependence of ethosuximide’s effect on Tau V337M locomotion. Thrashing assays were performed on age-synchronised animals grown in the
presence or absence of 2 mg/ml ethosuximide (n = 30-50 worms per data point). Data are shown as mean ± SEM (***p < 0.001, *p < 0.05).
e Ethosuximide increases lifespan in Tau V337M worms. Viability of age-synchronised animals grown in the presence of the indicated
concentrations of ethosuximide was determined in comparison to untreated wild type control CZ1200 worms (n = 50-102 worms for each
drug concentration). f Comparison of the ethosuximide concentration-dependence of mean lifespan extension in dnj-14 and Tau
V337M worms
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dnj-14 mutants – although wild type lifespan was not
significantly affected at any concentration (Fig. 1f ).
Ethosuximide action is independent of T-type calcium
channels
The efficacy of ethosuximide in generalised absence epi-
lepsy is thought to be due to blockade of the low voltage
activated T-type calcium channel [30]. C. elegans CCA-1
is most similar to the vertebrate T-type calcium channel
α1 subunit (42 % identity), with typical T-type kinetics,
voltage dependence and pharmacology [31]. We there-
fore constructed a double mutant Tau V337M; cca-
1(ad1650) strain to determine if ethosuximide’s thera-
peutic action in the frontotemporal dementia model was
mediated via inhibition of CCA-1. We chose to use the
Tau model because it is extremely challenging technically
to cross cca-1 with dnj-14 mutants, as both genes are
located on the X chromosome. As seen in Fig. 2a, loss of
cca-1 had minimal effect on Tau proteotoxicity, as a similar
large percentage of both Tau V337M; cca-1(ad1650) homo-
zygotes and Tau V337M transgenic worms exhibited se-
verely impaired motility. In contrast, both cca-1(ad1650)
single mutant control and heterozygous cross progeny did
not exhibit any motility defects. Ethosuximide treatment
mitigated the impaired motility of Tau V337M transgenic
worms and double mutants harboring a loss-of-function
mutation of cca-1 to a similar extent, both at day 1 and day
3 (Fig. 2a). Tau V337M; cca-1(ad1650) double mutants and
Tau V337M transgenic worms displayed a mean adult
lifespan of 12.1 and 12.6 days, respectively. Following etho-
suximide supplementation, there was negligible change in
lifespan of cca-1(ad1650) single mutant control worms.
However, the ability of ethosuximide to increase longevity
in the single Tau V337M transgenic strain was maintained
in the Tau V337M; cca-1(ad1650) homozygotes, signifi-
cantly extending the mean lifespan by 25 % and 16 %, re-
spectively (Fig. 2b). Taken together, these results indicate
that the mechanism of ethosuximide action does not in-
volve inhibition of CCA-1.
Protective effects of ethosuximide are not due to changes
in the E. coli food source
One contributor to late-age mortality in C. elegans is the
detrimental effect of their E. coli food source, and drugs
that decrease bacterial pathogenicity extend worm life-
span [32]. In addition, it has recently been shown that
some drugs, for example metformin, increase C. elegans
lifespan indirectly via changes to E. coli metabolism [33].
To determine if such bacterial effects contribute to the
mechanism of action of ethosuximide in lifespan exten-
sion, we used the antibiotic kanamycin to kill the OP50
food source and thus prevent both bacterial metabolism
and pathogenicity. In single treatments, kanamycin and
ethosuximide increased the mean lifespan of Tau V337M
worms by 37 % and 48 %, respectively (Fig. 2c). A com-
bined treatment of kanamycin and ethosuximide caused
a significant and approximately additive 72 % extension
in mean lifespan. As kanamycin clearly did not affect the
ability of ethosuximide to increase lifespan (Fig. 2c;
Additional file 1: Table S1), this suggests that ethosuxi-
mide’s protective effects are independent of bacterial
metabolism and pathogenicity.
Ethosuximide affects Tau protein solubility
In view of the general association between protein mis-
folding/aggregation and neurodegeneration, we reasoned
that ethosuximide’s therapeutic activity might be linked
to improved proteostasis. We therefore tested whether
ethosuximide could influence the aggregation of mutant
Tau protein in the worm frontotemporal dementia
model. As shown in Fig. 2d, there was no reduction in total
Tau levels in ethosuximide treated Tau transgenic worms
as compared to vehicle controls. The rescuing effect of
ethosuximide is therefore not due to transgene suppression
or reduced expression of toxic mutant Tau protein. We
then subjected both vehicle- and ethosuximide-treated
Tau V33M transgenic worms to a regimen of sequen-
tial extractions with buffers of increasing solubilising
strengths, as previously described [29]. Quantification
of the amount of soluble and insoluble (RIPA-extractable)
Tau relative to total Tau levels revealed a significant re-
duction in aberrantly-folded, insoluble Tau and a corre-
sponding increase in soluble Tau in ethosuximide-treated
compared with untreated worms (Fig. 2e,f). Therefore,
ethosuximide’s protective effects on motility and longevity
are accompanied by improved Tau proteostasis.
Ethosuximide modulates expression of DAF-16 target
genes
To gain insight into ethosuximide’s mechanism of action,
we took an unbiased transcriptomic approach using whole
genome C. elegans DNA microarrays. Two control strains
(N2 and CZ1200) and two ANCL model strains (dnj-14
ok237 and tm3223 alleles) were age-synchronised and
treated with 1 mg/ml ethosuximide or vehicle control.
Gene expression profiling was then used to identify
ethosuximide-responsive differentially expressed genes
(DEGs) in 6-day-old animals (Additional file 3: Figure S2).
Principal component analysis confirmed tight grouping of
the triplicate biological samples for each strain and a
consistent effect of ethosuximide, as illustrated in the
array correlation heatmap (Additional file 4: Figure S3A-C).
In order to stringently select for the most consistent and
significant ethosuximide-regulated transcripts, we focused
on DEGs common to at least 3 out of 4 strains using a 1 %
false discovery rate (FDR) cut-off. This yielded 125 DEGs,
comprising 61 up-regulated and 64 down-regulated genes.
Restricting our analysis still further to transcriptional
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changes common to all four strains yielded 60 DEGs con-
taining 40 up-regulated and 20 down-regulated genes, as
illustrated in Additional file 4: Figure S3D,E. The complete
data are shown in Additional file 5: Dataset S1.
DEGs that showed at least a 2-fold change in all strains
were considered the most significant ethosuximide-
responsive genes and are listed in Table 1. Given the known
neuroprotective effect of inhibiting the DAF-2 insulin/IGF
signalling (IIS) pathway, it was notable that the upregulated
genes included four members of the dod (downstream of
daf-16) gene class associated with the DAF-2 signalling
pathway; asm-3, a regulator of the DAF-2 pathway; and ttr-
Fig. 2 Ethosuximide acts independently of T-type calcium channels and bacterial metabolism to reduce Tau aggregation. a Ethosuximide Inhibition of the
T-type calcium channel, CCA-1, is not required for protection against paralysis. Tau V337M transgenic animals were crossed with loss-of-function mutations
for cca-1(ad1650) to generate homozygous cross progeny. Ethosuximide supplementation increased thrashing activity of the Tau V337M transgenic strain
and the double mutant Tau V337M; cca-1(ad1650) strain to similar extents. Data are shown as mean ± SEM (**p< 0.01, *p< 0.05; n = 30-50 worms per data
point). b Ethosuximide extends lifespan in Tau V337M mutants in the absence of CCA-1. Lifespan assays were performed on single mutant cca-1(ad1650),
transgenic (Tau V337M) and double mutant Tau V337M; cca-1(ad1650) strains grown in the presence (dashed lines) or absence (solid lines) of 1 mg/ml
ethosuximide (n > 100 worms per strain/condition). c Ethosuximide extends lifespan using killed bacteria as a food source. Lifespan assays were performed
on Tau V337M worms grown under control conditions or in the presence of kanamycin, or 1 mg/ml ethosuximide or both (n > 80 worms per condition).
d Total Tau protein expression in Tau V337M worm lysates is not reduced by ethosuximide. The left panel shows a representative western blot; the right
panel shows quantification of Tau normalised to actin and expressed as % of untreated control (mean ± SEM, n = 3; not significant). e, f Ethosuximide
affects Tau proteostasis. e shows a representative western blot of the soluble and detergent-soluble (RIPA) sequentially extracted fractions in the presence
or absence of ethosuximide treatment. f shows quantification of Tau fractions normalised to actin and expressed as % of the total (soluble + RIPA) protein
level (data are shown as mean ± SEM (n = 3; *p< 0.05)
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44, which is upregulated in long-lived daf-2 mutants. The
most strongly down-regulated transcripts were either
uncharacterised genes or individual genes associated
with diverse cellular processes, for example ubiquiti-
nation (fbxb-66). Seven of the up-regulated genes
identified in our microarray experiments were chosen
for validation using qRT-PCR. Significantly increased
expression by qRT-PCR was observed for all 7 genes,
thus confirming the microarray data (Fig. 3a). In con-
trast, qRT-PCR analysis showed no change in the ex-
pression level of pph-6 (chosen as a negative control
based on our microarray data) or of two normalising
genes: pmp-3 and act-1.
Functional annotation enrichment analysis of DEGs
shared by at least 3 treated strains was used to subdivide
the ethosuximide-responsive transcripts into groups
based on Gene Ontology (GO) identifiers (Additional file
6: Figure S4). Both DAVID and modMine GO analyses
yielded a significant enrichment for GO terms related to
“lipid glycosylation”, “lipid modification”, “oxidation reduc-
tion”, “determination of adult lifespan” and “chromatin
assembly”. DEGs up-regulated in response to ethosuximide
exposure clustered into four groups with significant enrich-
ment scores (Additional file 6: Figure S4A). Cluster 1 con-
tained eight cytochrome P450 genes (cyp-14A3, cyp-34A2,
cyp-34A9/dod-16, cyp-35B1/dod-13, cyp-35C1, cyp-33A1,
Table 1 Gene expression changes induced by ethosuximide in all microarray experiments
Selected criteria for inclusion were a FDR corrected p-value less than 0.01 and a calculated mean fold-change (FC) in expression greater than 2 or less than -2 in
all four strains analysed. Red shading indicates up-regulated genes; green shading indicates down-regulated genes
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cyp-35A2, cyp-35A3), three short chain dehydrogenase
genes (dhs-23, dhs-26, dhs-2) and an aldehyde dehydrogen-
ase (alh-5). These enriched genes (Additional file 7: Figure
S5) share annotation terms relating to oxidoreductase activ-
ity, ion binding and multicellular organismal ageing. Clus-
ters 2 and 3 are overlapping and contain the same group of
6 putative UDP-glucuronosyl/glucosyl transferases (UGTs)
involved in lipid and phase II metabolism (F08A8.2, ugt-51,
ugt-8, ugt-41, ugt-14, ugt-25). Cluster 4 is associated with
the term ageing and lifespan determination and comprised
cyp-34A9, cyp-35B1, dod-6, dod-3, and ftn-1, which are
amongst the most responsive downstream targets of DAF-
16/FOXO; and thn-1 and spp.-1. DEGs down-regulated in
response to ethosuximide showed a significant enrichment
to chromatin remodelling and related functional categories
encompassing “cellular macromolecular complex assembly,
chromatin assembly or disassembly, DNA packaging, nu-
cleosome assembly, chromatin organisation, and chromatin
assembly” (Additional file 6: Figure S4). Enriched genes
(Additional file 7: Figure S5) include an H2B histone (his-8)
and H1 linker histone variants (his-24, hil-2, hil-3, hil-7)
which play roles in heterochromatin packaging and gene
regulation. modMine publication enrichment analysis
(Additional file 6: Figure S4C) further revealed a significant
enrichment for DAF-16 target genes.
Analysis of the upstream promoter regions of
ethosuximide-responsive DEGs using Regulatory Se-
quence Analysis Tools (RSAT) revealed that the most
significantly enriched motif was CTTATCA (Fig. 3b).
This is the consensus sequence for the DAF-16-associated
element (DAE), which is overrepresented in the promoters
of DAF-16-regulated target genes downstream of DAF-2
in the IIS pathway [34]. RSAT also identified accessory
motifs that co-occurred with DAE, which appear to be
Fig. 3 Ethosuximide-induced genes are enriched in DAF-16-
associated elements and ethosuximide-induced lifespan extension
requires daf-16. a Validation of gene expression changes using
qRT-PCR. Selected genes that were up-regulated by ethosuximide in
microarray experiments (ugt-25, dhs-26, cyp-14A3, cyp-35B1, ttr-44,
dod-6 and cyp-34A9) were confirmed to be significantly induced
using qRT-PCR. No significant changes in expression of normalisation
(act-1, pmp-3) or negative control (pph-6) genes was observed.
Results are expressed as mean fold change ± SEM relative to the
unexposed control (n = 3). b Ethosuximide-responsive genes are
enriched for the DAF-16 Associated Element (DAE) motif. To identify
regulatory sequences correlating with ethosuximide-responsiveness,
200-bp regions in the upstream promoter sequences of common
DEGs were mined for overrepresented motifs using RSAT. c Ethosuximide
increases dnj-14 lifespan in a daf-16-dependent manner. Survival curves
of dnj-14(ok237) worms grown on E. coli containing empty vector
(L4440), hsp-1 or daf-16 dsRNA-producing plasmids in the presence
(dashed lines) or absence (solid lines) of 1 mg/ml ethosuximide.
Ethosuximide treatment significantly increased the lifespan of
dnj-14(ok237) worms on vector control (p < 0.001), but had no
significant effect on daf-16 RNAi animals (p > 0.15) (n > 100
worms per strain/condition)
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core promoter sequence elements in C. elegans (Additional
file 8: Figure S6). No additional motifs were identified using
3 other tools (MEME-DREME, SCOPE, BioProspector)
and indeed DAE and its variants was the only regulatory
sequence identified by all four sequence analysis tools
(Additional file 8: Figure S6).
Ethosuximide’s protective effect requires DAF-16
Subjecting C. elegans to mild stress can increase longev-
ity via hormesis. However, comparing our microarray
data with the literature (Additional file 9: Figure S7), it is
evident that the transcriptomic effect of ethosuximide
was inconsistent with a general stress response. Further-
more, ethosuximide did not induce oxidative stress and
the consequent transcriptional induction of SKN-1 tar-
get genes, as evidenced by microarray data (Additional
file 9: Figure S7), confirmatory qRT-PCR (Additional file
10: Figure S8A) and the lack of activation of a GFP
reporter of the SKN-1 target, gst-4 (Additional file 10:
Figure S8B). Finally, paraquat and juglone applied at
concentrations that have previously been shown to result
in hormesis-induced lifespan extension did not rescue
the dnj-14 mutant despite inducing strong Pgst-4::GFP
expression (Additional file 10: Figure S8C).
As our microarray data had revealed DAF-16 target
gene modulation as a major consequence of ethosuxi-
mide application, we set out to test if DAF-16 was re-
quired for ethosuximide-mediated protection. We were
unable to obtain stable lines of homozygous double mu-
tants for both dnj-14(ok237) and daf-16(mu86), as the
putative double mutants exhibited severe developmental
problems and extremely low brood size (Additional file
11: Figure S9), suggesting a synthetic lethal genetic inter-
action. We therefore used RNAi to knockdown expres-
sion of daf-16, which resulted in a significant reduction
in lifespan of both wild type and dnj-14(ok237) worms
(Fig. 3c; Additional file 12: Figure S10). Ethosuximide
treatment of dnj-14(ok237) worms on L4440 vector con-
trol RNAi bacteria caused a robust lifespan extension;
but, strikingly, daf-16 RNAi abolished this effect (Fig. 3c).
RNAi of hsp-1, which encodes an Hsp70 protein, also
reduced lifespan, but this was significantly increased by
ethosuximide (Additional file 12: Figure S10), indicating
both that ethosuximide acts independently of hsp-1 and
that inhibition by daf-16 RNAi is not a general conse-
quence of RNAi. These data therefore suggest that DAF-
16 is essential for the therapeutic action of ethosuximide.
To investigate if ethosuximide affects the subcellular
localisation of DAF-16, we examined the effect of the
drug on a strain containing a DAF-16-GFP reporter
(Additional file 13: Figure S11). Although we could ob-
serve nuclear translocation of DAF-16-GFP in response to
heat shock and starvation, we were unable to detect an
obvious effect of ethosuximide. It is important to note,
however, that this does not affect the conclusion that
ethosuximide’s action requires DAF-16 activity. For ex-
ample, the classical IIS mutant age-1(hx546), which abso-
lutely requires DAF-16 for lifespan extension, also does not
exhibit increased nuclear DAF-16-GFP [35]. It is possible
that the effect of ethosuximide on nuclear enrichment of
DAF-16-GFP or the amount of nuclear DAF-16/FOXO
required for the effects on lifespan might simply be below
the detection threshold in this type of experiment.
Ethosuximide modulates mammalian FOXO target gene
expression
Given that DAF-16/FOXO is conserved between C. elegans
and mammals, we tested whether ethosuximide could affect
the transcriptional activity of mammalian DAF-16 homo-
logues (FOXO1, FOXO3, and FOXO4). FOXOs have been
shown to modulate cell cycle arrest, apoptosis, autophagy,
angiogenesis, differentiation, stress resistance, insulin sig-
nalling, stem cell maintenance and metabolism [36]. Nine
classical mammalian FOXO target genes involved in
cell cycle regulation (Ccng2, Cdkn1a, Cdkn1b, Rbl2),
DNA repair (Gadd45a), apoptosis (Bim), stress re-
sponse (Cat, Sod2) and insulin signalling (Eif4ebp1)
were selected and their mRNA levels in a differenti-
ated mouse neuroblastoma cell line (N2A) following
ethosuximide exposure were then measured using
qRT-PCR. There was no significant change in gene ex-
pression at 0.1 mg/ml, but at 0.56 mg/ml (the optimal
concentration that stimulates neuronal differentiation in
stem cells [37]) and 1 mg/ml (the optimal concentration
in our worm ND models) ethosuximide significantly up-
regulated the mRNA expression of FOXO target genes in-
volved in cell cycle regulation (Ccng2, Cdkn1b, Rbl2) and
DNA damage repair (Gadd45a) (Fig. 4a). Therefore, the
ability of ethosuximide to modulate DAF-16/FOXO target
gene expression is conserved from worms to mammals.
Ethosuximide suppresses protein aggregation in
mammalian neurons
To determine if ethosuximide could also affect proteos-
tasis in mammalian neurons, we transfected N2A cells
with EGFP-tagged polyglutamine (polyQ) constructs and
monitored aggregate formation over time in culture [38].
PolyQ25 barely aggregated either in the presence or
absence of ethosuximide, as GFP staining was evenly dis-
tributed throughout the cytosol (Fig. 4b). In contrast,
there was a progressive increase in the number of cells
with polyQ97 aggregates, with intracellular GFP punctae
readily observable in the cytoplasm of most polyQ97-
transfected N2A cells after 72 h (Fig. 4b, Additional file
14: Figure S12). When aggregates appeared, cells tended
to round up and GFP-fluorescence in the cytosol was re-
stricted to bright punctae. Ethosuximide treatment ap-
peared to antagonise aggregate formation and to increase
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diffuse cytosolic GFP staining in the soma and neuronal
processes, suggesting that it enhanced the solubility of
polyQ97. To quantify this, individual GFP aggregates were
counted and the percentage of polyQ-EGFP transfected
N2A cells bearing fluorescent aggregates was determined.
Ethosuximide treatment significantly reduced the fraction
Fig. 4 Ethosuximide induces FOXO target gene expression and reduces polyglutamine protein aggregation in mammalian neurons. a mRNA levels of
classical FOXO target genes were analysed by qRT-PCR in differentiated mouse N2A neuroblastoma cells treated with the indicated concentrations of
ethosuximide. Data are shown as mean ± SEM (n = 3; *p≤ 0.05, **p≤ 0.01). (b-c) Ethosuximide reduces polyglutamine protein aggregation. b Visualisation
of EGFP-tagged non-pathological (polyQ25) and pathological (polyQ97) polyglutamine tracts in N2A cells 72 h post-transfection. Phase contrast, GFP
(green) and SYTOX orange staining (red, to identify dead cells) confocal images are shown to illustrate that aggregates are specific to polyQ97 and that
ethosuximide redistributed polyQ97-EGFP away from aggregates into the cytoplasm and neuronal processes C) Quantification of polyQ aggregation. The
number of polyQ-EGFP transfected N2A cells bearing fluorescent aggregates as a percentage of the total number of viable transfected (green) cells was
counted at the indicated post-transfection times. Cell/aggregate counting was performed manually and confirmed using ImageJ software if cells were
sufficiently sparse to allow this. Data are shown as mean ± SEM (n = 3, counting ~100 cells in each experiment; *p< 0.05)
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of transfected cells containing aggregates by 20 % com-
pared with the vehicle control (Fig. 4c), although neuronal
viability as quantified by SYTOX Orange staining was un-
affected by ethosuximide (Additional file 15: Figure S13).
Therefore, ethosuximide can antagonise protein aggrega-
tion in worm neurons in vivo and in mammalian neurons
in vitro.
Discussion
Neurodegenerative diseases are increasingly common
and exert large costs on society. However, no disease-
modifying therapies for these devastating disorders are
currently available. Hence, there is considerable current
interest in the idea of repurposing existing medicines for
the treatment of neurodegeneration [8]. Drugs that can
mitigate the impact of common pathological processes
such as protein misfolding/aggregation that underlie
multiple neurodegenerative diseases could be especially
useful therapeutics. Ethosuximide may be a candidate for
such a repurposing approach. We have shown here that
ethosuximide ameliorates the phenotypes of two distinct
worm neurodegenerative disease models based on dele-
tion of an endogenous neuroprotective gene (dnj-14) and
pan-neuronal expression of a disease-associated mutant
Tau protein. Furthermore, an independent study has re-
cently reported a neuroprotective effect of ethosuximide
against human mutant mTDP-43-mediated proteotoxicity
in a transgenic C. elegans model of amyotrophic lateral
sclerosis [15]. Importantly, we have discovered that etho-
suximide also reduces polyglutamine protein aggregation
in mammalian neuroblastoma cells and acts by modulat-
ing DAF-16/FOXO target gene expression in both worms
and mammalian neurons. These evolutionarily conserved
effects on so many different neurodegenerative disease
models suggest that ethosuximide merits consideration
for therapeutic applications in patients. Indeed, given the
difficulty of distinguishing between tau- and TDP-43-
associated frontotemporal dementia in the clinic, a drug
with potential to protect against both pathologies could be
particularly useful. Future experiments in mouse neurode-
generation models should therefore be given a high priority
in order to validate ethosuximide’s repurposing potential
for treatment of human neurodegenerative diseases.
The mechanism by which ethosuximide exerts its anti-
epileptic action is unclear and controversial. Ethosuxi-
mide has long been thought to act by blocking T-type
calcium channels; however, more recent work has sug-
gested that actions on other voltage-sensitive ion chan-
nels, such as sodium and potassium channels, are
involved in the therapeutic effect of ethosuximide [30].
Our finding that the beneficial effects of ethosuximide
on motility and longevity in a frontotemporal dementia
model persist in strains harbouring a null mutation in
the C. elegans T-type calcium channel, cca-1, suggests
that ethosuximide’s neuroprotective activity is not medi-
ated by inhibition of T-type channels. This conclusion is
supported by previous work in C. elegans showing that
lifespan extension by ethosuximide is unaffected by a dif-
ferent mutant allele of cca-1 [39]. Although we cannot
rule out redundancy with other channel subunit homologs
that share a putative ethosuximide binding site, given that
the C. elegans genome does not encode voltage-sensitive
sodium channels [40], it seems likely that ethosuximide
ameliorates neurodegeneration via a distinct mechanism.
Ethosuximide has previously been suggested to extend
lifespan in wild type worms via inhibition of chemosen-
sory neurons [39, 41], resulting in a perceived state of diet-
ary restriction and hence lifespan increase [39]. However,
ethosuximide’s ability to extend lifespan persists even
under maximal dietary restriction conditions [42], thus
arguing against this mechanism. In our study, lifespan in
wild type control worms was unaffected by ethosuximide,
but nevertheless the protective effect of ethosuximide in
worm neurodegeneration models is unlikely to involve
inhibition of chemosensory neurons, as the dnj-14 model
used in this study already exhibits profound chemosensory
impairment, which is actually rescued by ethosuximide.
The transcriptomic analysis reported here suggests in-
stead that ethosuximide acts by modulating the expres-
sion of DAF-16/FOXO target genes. DAF-16/FOXO is a
conserved transcription factor acting downstream of
DAF-2 in the IIS pathway [36]. Reducing IIS pathway
activity by inhibiting DAF-2 causes an increase in DAF-16
activity and the consequent modulation of DAF-16 target
gene expression leads to phenotypic changes such as in-
creased lifespan. In addition to its pivotal role in longevity
and stress resistance, reduced IIS pathway activity has
been shown to confer neuroprotection in nematode neu-
rodegeneration models based on expression of Aβ [43],
TDP-43 [44] and polyQ [45]; and also in mouse Aβ
models [46]. Our finding that the neuroprotective effect of
ethosuximide in vivo was dependent on DAF-16 function
is consistent with these studies and also with our tran-
scriptomic analysis. It is also consistent with the recent
observation that ethosuximide’s protective effect on a
C. elegans amyotrophic lateral sclerosis model re-
quires DAF-16 [15], but contrasts with earlier work
showing that ethosuximide still increases lifespan in
daf-16 mutants [41]. Although we observed little effect
of ethosuximide on skn-1 pathway targets or on oxidative
stress detoxification genes such as catalase, superoxide
dismutases and peroxiredoxins, genes that are commonly
regulated by DAF-16 and oxidative stress showed some
enrichment (Additional file 9: Figure S7), which may be
relevant given the established links between oxidative stress
and protein aggregation in neurodegenerative disease
models. Ethosuximide may mimic some of the effects of
reduced IIS by inducing the expression of neuroprotective
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DAF-16 target genes, in particular those containing the
DAE motif [47].
Analogous to its ability to regulate DAF-16 target gene
expression and modulate protein aggregation in C. ele-
gans, we found that ethosuximide induces transcription
of FOXO target genes and confers protection against
polyQ aggregation in mammalian neuronal cell lines.
This therefore suggests an evolutionary conservation of
DAF-16/FOXO-regulated ethosuximide responses. The
DAF-16 homologue FOXO3a is highly expressed in
adult brain, and plays key regulatory roles in neuronal
survival under basal, stress and disease conditions [48,
49]. Furthermore, FOXO3a contributes to neuroprotec-
tion by Sirt1 in a striatal cell model of Huntington’s dis-
ease [50] and moderate FOXO3 activation was recently
shown to oppose α-synuclein accumulation and proteo-
toxicity [51].
Ethosuximide is cheap to manufacture, has been widely
prescribed for several decades, is well tolerated at high
doses and has a good safety record – indeed, it is often
used in children to treat absence seizures [52]. Further-
more, it has >95 % bioavailability and freely crosses the
blood-brain barrier, with levels of the drug in cerebro-
spinal fluid and multiple brain regions being similar to
those found in plasma [52]. Optimal improvement in the
C. elegans models described here was seen at an externally
applied concentration of 1-2 mg/ml, which equates to a
measured internal concentration within the worm of 15-
30 μg/ml [41]; while effects in mammalian neurons were
seen at 0.5-1 mg/ml. These values are close to the thera-
peutic dose range of ethosuximide for epilepsy in humans
(40-100 μg/ml) [52], suggesting that neuroprotective doses
could be achieved in patients. Ethosuximide may therefore
be a candidate drug for repurposing as a treatment for
neurodegenerative diseases.
Conclusion
We have shown here that ethosuximide has neuropro-
tective activity on multiple neurodegeneration models
ranging from worms to mammalian cultured neurons.
Furthermore, we have revealed that this anti-epileptic
drug has an evolutionarily conserved effect in modulat-
ing DAF-16/FOXO target gene expression; and that
DAF-16 is essential for ethosuximide’s therapeutic action
in the worm dnj-14 model. Ethosuximide is off-patent,
has a good safety record and freely permeates the
blood-brain barrier; and so could potentially be rapidly
repurposed for other neurological indications. Future
experiments in established mouse neurodegeneration
models should therefore be a high priority to validate
the repurposing potential of this well-established anti-
epileptic drug for treatment of human neurodegenera-
tive diseases.
Materials and methods
Experimental design
This study aimed to investigate if ethosuximide had
general neuroprotective activity and to shed light on its
mechanism of action. To address this question, we initially
performed drug screening in the dnj-14 worm neurodegen-
eration model that we developed, using chemotaxis and
lifespan assays. Subsequently, the effect of ethosuximide
was investigated on a transgenic worm model of FTD,
using motility and lifespan assays and determination of tau
protein aggregation by western blot analyses. Transcrip-
tomic effects of ethosuximide were analysed on identical
numbers of age-matched control and treated animals using
Affymetrix C. elegans GeneChips, then validated by qRT-
PCR using independent biological samples. Differentially
expressed genes were identified using the statistical analysis
tools R, Affy and limma. Functional annotation and cluster-
ing of putative ethosuximide target genes was performed
using the DAVID and modENCODE Modmine bioinfor-
matic suites; and predictions tested by C. elegans RNAi
experiments. Evolutionary conservation of ethosuximide’s
actions was assessed by qRT-PCR analysis and fluorescence
microscopy imaging of GFP-tagged polyglutamine aggrega-
tion using retinoic acid-differentiated mouse neuroblastoma
cells.
Maintenance and propagation of C. elegans strains
C. elegans strains were cultured on nematode growth
medium (NGM) culture plates seeded with the E. coli
strain OP50 at 20 °C unless stated otherwise. C. elegans
strains used in this study are detailed in Additional file 16:
Table S2, and were either obtained from Caenorhabditis
Genetics Center (CGC, University of Minnesota, USA,
generously provided by the indicated labs that generated
them, or constructed in-house.
Drug treatment
All chemicals were obtained from Sigma Chemical Co.
(St. Louis, MO). Ethosuximide was prepared as a con-
centrated stock solution in phosphate buffered saline
(PBS) and was added to molten NGM before pouring
into petri dishes. Vehicle control NGM plates containing
equivalent amounts of PBS were prepared at the same
time. Freshly poured drug plates were stored in the dark
at 4 °C until 1-2 days before use and then moved to
room temperature and seeded with E. coli OP50. Worms
were grown for two generations on drug plates to ensure
effective exposure. 10-20 gravid adults of test strains
were cultured in the presence of the drug to lay eggs for
6 h and then removed to set the eggs in synchrony.
Plates were grown at 20 °C for three days and selected
for analysis at the L4 stage (defined as day 0).
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Behavioural and lifespan assays
Motility and chemotaxis assays were performed as previ-
ously described [18, 28] on developmentally synchro-
nised worms. For lifespan assays, animals were scored
every 1-2 days for survival by examining for touch pro-
voked movement. Worms which did not display spon-
taneous movement or response to repeated touching
were scored as dead. Worms were transferred onto fresh
plates every 2 -4 days until the cessation of progeny pro-
duction. Dead worms that displayed internally hatched
progeny, an extruded gonad, or desiccation caused by
crawling off the agar were excluded from the data.
Sequential extraction of Tau protein
A detailed description is provided in Additional file 17.
Vehicle- and ethosuximide-treated Tau V337M worms
were lysed and separated into soluble and insoluble
(RIPA detergent-extractable) fractions, using previously
described methods [29]. Fractions were separated by
SDS-PAGE and western blotted using anti-human Tau
T46 (Invitrogen) and anti-actin (Sigma) antibodies. The
abundance of Tau protein in each fraction was quanti-
fied by densitometry and normalised against beta-actin.
Total Tau levels in lysates were expressed as the percentage
of actin-normalised Tau relative to vehicle control lysates;
Tau levels in sequentially extracted fractions were expressed
as the percentage of actin-normalised Tau relative to the
sum of both fractions (soluble + RIPA) combined.
Genetic crosses
N2 males were mated with CK10 Paex-3::Tau V337M;
Pmyo-2::GFP hermaphrodites; and the resulting trans-
genic male offspring were then back-crossed to isolate
homozygous GFP (-Tau)-expressing males. These were
then mated with cca-1(ad1650) hermaphrodites and their
progeny genotyped to identify homozygous transgenic
double mutants via PCR using primers flanking the cca-
1(ad1650) deletion [forward: 5’-CCGCAATTTGCCCTCC
ACAT-3’; reverse: 5’-ATGAGGATGGCGAAGAGGACC-
3’] and primers based on the human MAPT gene that en-
codes Tau (forward: 5’-CAAGCTCGCATGGTCAGT AA-
3’; reverse: 5’-TTCTCAGTGGAGCCGATC TT-3’).
RNA interference
RNAi experiments were conducted using a previously
described feeding protocol [53]. Worms were grown on
HT115 (DE3) bacteria expressing pG-L4440-based plas-
mids from the C. elegans Open Reading Frame (ORF)
RNAi feeding library (Source Bioscience, Nottingham,
UK). ORF inserts were verified by restriction endonucle-
ase digest prior to use. RNAi treatments were performed
as whole-life treatments and second generation RNAi-fed
worms were synchronised on fresh RNAi plates supple-
mented with test compound (ethosuximide) or vehicle
(PBS). Feeding of HT115 carrying the pG-L4440 vector
without an insert (L4440) served as the empty vector
negative control.
Transcriptomic work
A detailed description is provided in Additional file 17.
Briefly, worms were grown on vehicle- or ethosuximide-
containing NGM plates until age day 6. RNA was then
extracted, amplified, labelled and hybridised to Affymetrix
C. elegans GeneChips (Affymetrix, High Wycombe, UK).
Three independent biological replicate samples were used
for each strain and condition (24 gene arrays in total).
Sequences 200 bp upstream of C. elegans DEGs were
analysed to identify shared DNA motifs using Regulatory
Sequence Analysis Tools (RSAT; http://rsat.bigre.ulb.ac.be/
rsat/), MEME (http://meme-suite.org/), BioProspector
(http://seqmotifs.stanford.edu) and SCOPE (http://genie.
dartmouth.edu/scope/). Microarray data are available in
the ArrayExpress database (www.ebi.ac.uk/arrayexpress)
under accession number E-MTAB-3919.
Quantitative real-time PCR (qRT-PCR)
A detailed description is provided in Additional file 17
and all qRT-PCR primers are listed in Additional file 18:
Table S3. act-1 and pmp-3, which showed no significant
changes in microarray analysis and have been extensively
used as normalising genes in differential expression stud-
ies in C. elegans [54], were chosen as reference genes.
RNA was extracted and used to prepare cDNA, which
was then used for SYBR® Green-based real-time PCR
using an IQ5 detection system (Bio-Rad). All qRT-PCR
reactions were carried out on 3 biological replicates with
three technical replications. Transcript expression was
analysed using Bio-Rad CFX Manager 3.0 software and
relative expression was calculated by normalising the Ct
values for test genes to reference genes.
Mammalian cell methods
A detailed description is provided in Additional file 17.
For qRT-PCR analysis, mouse Neuro2A (N2A) neuro-
blastoma cells were cultured on 6-well plates and treated
with retinoic acid to induce neuronal differentiation.
After 24 h, N2A cells were treated with vehicle control
(PBS) or increasing concentrations of ethosuximide for 5 h.
Total RNA was then isolated, DNase-treated and reverse
transcribed to cDNA. qRT-PCR was run as described above
normalising to the reference genes glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and β-actin (ACTB).
Three independent biological replicates were used for
qRT-PCR. For microscopy, N2A cells were grown on
glass-bottom 35-mm dishes and treated with retinoic acid
to stimulate neuronal differentiation prior to transient
transfection with polyQ97-eGFP or polyQ25-eGFP plas-
mids construct using PromoFectin transfection reagent
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(PromoKine). Live transfected cells were imaged using
a Leica AOBS SP2 microscope (Leica Microsystems,
Heidelberg, Germany) and the percentage of live cells
with visible GFP aggregates determined at 24, 48 and
72 h post-transfection. A minimum of 50 cells per con-
dition were counted manually and the calculated per-
centage of transfected cells containing GFP aggregates
was derived from three independent experiments.
Neuronal viability was visualised by SYTOX Orange®
staining (Invitrogen) and the percentage cell death cal-
culated by manually counting the number of labelled
cells from a total of at least 800 cells per condition
imaged over three independent experiments.
Statistical analysis
Statistical analysis of lifespan data was performed using
the log-rank (Mantel-Cox) test, and mortality at specific
time points was compared using Fisher’s exact test. For
behavioural assays, if two data sets were being directly com-
pared, Student’s t-test was used; for comparison of multiple
data sets, one-way analysis of variance (ANOVA) was used.
For transcriptomic data, a significance test of the estimated
fold change for each contrast was performed by the empir-
ical Bayes function packed in limma, and p-values were
adjusted using the Benjamini and Hochberg false discovery
rate (FDR) control approach to deal with the effect of mul-
tiple tests [55]. Genes with a FDR corrected p-value equal
to or less than 0.01 and fold change greater than 2 were
deemed significantly differentially expressed.
Additional files
Additional file 1: Table S1. Statistical analysis of lifespan experiments
in C. elegans. (PDF 103 kb)
Additional file 2: Figure S1. Ethosuximide does not increase lifespan
or sensorimotor function in wild type C. elegans strains. (PDF 1430 kb)
Additional file 3: Figure S2. Transcriptomics workflow. (PDF 1368 kb)
Additional file 4: Figure S3. Whole-genome expression profiling of
dnj-14(ok237), dnj-14(tm3223), CZ1200 and N2 strains treated with
ethosuximide. (PDF 1542 kb)
Additional file 5: Dataset S1.Transcriptomic data. (XLSX 939 kb)
Additional file 6: Figure S4. Functional enrichment analysis of
common DEGs. (PDF 1365 kb)
Additional file 7: Figure S5. DEGs derived from highly enriched
functional clusters. (PDF 33 kb)
Additional file 8: Figure S6. Ethosuximide-responsive genes are
enriched for a DAF-16 Associated Element (DAE) motif. (PDF 145 kb)
Additional file 9: Figure S7. Data set associations. (PDF 1374 kb)
Additional file 10: Figure S8. Ethosuximide does not induce general
stress and hormesis. (PDF 1626 kb)
Additional file 11: Figure S9. Negative genetic interactions between
dnj-14 and daf-16. (PDF 1580 kb)
Additional file 12: Figure S10. Ethosuximide action is independent of
hsp-1. (PDF 98 kb)
Additional file 13: Figure S11. Ethosuximide does not cause obvious
nuclear translocation of GFP-tagged DAF-16. (PDF 1626 kb)
Additional file 14: Figure S12. Ethosuximide reduces polyglutamine
protein aggregation in mammalian neurons. (PDF 2095 kb)
Additional file 15: Figure S13. Ethosuximide has no significant effect
on cytotoxicity in mammalian neurons. (PDF 33 kb)
Additional file 16: Table S2. C. elegans strains used in this study.
(PDF 12 kb)
Additional file 17: Supplementary Methods. (PDF 70 kb)
Additional file 18: Table S3. Sequences of oligonucleotides used in
this study. (PDF 27 kb)
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
XC, HVM, SW and SSK performed the experiments. XC, HVM, BK, JWB, RDB
and AM analysed and interpreted the data. BK provided essential reagents
and materials. AM, RDB and JWB conceived and designed the experiments.
AM and XC wrote the manuscript with input from all of the other authors.
All authors read and approved the final manuscript.
Acknowledgements
This work was supported by grants from the BBSRC (RDB, AM and JWB) and
Research into Ageing (AM). XC was supported by a BBSRC PhD studentship.
SW is supported by a Wellcome Trust PhD studentship. SSK was supported
by the Research into Ageing Fund, a fund set up and managed by Age UK.
Strains used in this work were provided by the Caenorhabditis Genetics
Center, which is funded by the NIH National Center for Research Resources
(NCRR) and by the National Bioresource Project for the Experimental Animal
“Nematode C. elegans” based in the lab of Dr Shohei Mitani (Tokyo Women’s
Medical University, Tokyo, Japan). We acknowledge the help of Dr Lucille
Rainbow and Dr Fang Yongxiang from the University of Liverpool Centre for
Genomic Research, who performed the C. elegans Affymetrix GeneChip
arrays and statistical analysis. We are grateful to Steve High (University of
Manchester) and Ron Kopito (Stanford University) for providing plasmids and
to James Johnson (University of Manchester) for technical advice and help.
We also thank Andy Cossins (University of Liverpool) and Gene Schuster
(University College London) for advice on microarrays; and Jane Rees
(University of Liverpool) for constructive comments on the manuscript.
Author details
1Department of Cellular and Molecular Physiology, Institute of Translational
Medicine, University of Liverpool, Crown St, Liverpool L69 3BX, UK. 2Geriatrics
Research Education and Clinical Center, Seattle Veterans Affairs Puget Sound
Health Care System and University of Washington Department of Medicine,
1660 South Columbian Way, Seattle, WA 98108, USA. 3Present Address:
Centre for Neurodegenerative Science, Van Andel Research Institute, 333
Bostwick Avenue NE, Grand Rapids, MI 49503, USA.
Received: 23 March 2015 Accepted: 21 September 2015
References
1. Narayan P, Ehsani S, Lindquist S. Combating neurodegenerative disease
with chemical probes and model systems. Nat Chem Biol. 2014;10:911–20.
2. Link CD. Expression of human beta-amyloid peptide in transgenic
Caenorhabditis elegans. Proc Natl Acad Sci U S A. 1995;92:9368–72.
3. Nass R, Miller DM, Blakely RD. C. elegans: a novel pharmacogenetic model
to study Parkinson’s disease. Parkinsonism Relat Disord. 2001;7:185–91.
4. Satyal SH, Schmidt E, Kitagawa K, Sondheimer N, Lindquist S, Kramer JM,
et al. Polyglutamine aggregates alter protein folding homeostasis in
Caenorhabditis elegans. Proc Natl Acad Sci U S A. 2000;97:5750–5.
5. van Ham TJ, Breitling R, Swertz MA, Nollen EA. Neurodegenerative diseases:
lessons from genome-wide screens in small model organisms. EMBO Mol
Med. 2009;1:360–70.
6. Chen X, Burgoyne RD. Identification of common genetic modifiers of
neurodegenerative diseases from an integrative analysis of diverse genetic
screens in model organisms. BMC Genomics. 2012;13:71.
7. Zhang M, Luo G, Zhou Y, Wang S, Zhong Z. Phenotypic screens targeting
neurodegenerative diseases. J Biomol Screen. 2014;19:1–16.
Chen et al. Molecular Neurodegeneration  (2015) 10:51 Page 13 of 14
8. Corbett A, Pickett J, Burns A, Corcoran J, Dunnett SB, Edison P, et al. Drug
repositioning for Alzheimer’s disease. Nat Rev Drug Discov. 2012;11:833–46.
9. Lublin A, Link C. Alzheimer’s disease drug discovery: screening using as a
model for beta-amyloid peptide-induced toxicity. Drug Discov Today
Technol. 2013;10:e115–9.
10. McCormick AV, Wheeler JM, Guthrie CR, Liachko NF, Kraemer BC. Dopamine
D2 receptor antagonism suppresses tau aggregation and neurotoxicity. Biol
Psychiatry. 2013;73:464–71.
11. Sleigh JN, Buckingham SD, Esmaeili B, Viswanathan M, Cuppen E, Westlund
BM, et al. A novel Caenorhabditis elegans allele, smn-1(cb131), mimicking a
mild form of spinal muscular atrophy, provides a convenient drug screening
platform highlighting new and pre-approved compounds. Hum Mol Genet.
2011;20:245–60.
12. Wolozin B, Gabel C, Ferree A, Guillily M, Ebata A. Watching worms whither:
modeling neurodegeneration in C. elegans. Prog Mol Biol Transl Sci.
2011;100:499–514.
13. Voisine C, Varma H, Walker N, Bates EA, Stockwell BR, Hart AC. Identification
of potential therapeutic drugs for huntington’s disease using
Caenorhabditis elegans. PLoS One. 2007;2:e504.
14. Parker JA, Arango M, Abderrahmane S, Lambert E, Tourette C, Catoire H, et
al. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and
mammalian neurons. Nat Genet. 2005;37:349–50.
15. Tauffenberger A, Julien C, Parker JA. Evaluation of longevity enhancing
compounds against transactive response DNA-binding protein-43 neuronal
toxicity. Neurobiol Aging. 2013;34:2175–82.
16. Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE. Dietary
supplementation with resveratrol reduces plaque pathology in a transgenic
model of Alzheimer’s disease. Neurochem Int. 2009;54:111–8.
17. Bizat N, Peyrin JM, Haik S, Cochois V, Beaudry P, Laplanche JL, et al. Neuron
dysfunction is induced by prion protein with an insertional mutation via a
Fyn kinase and reversed by sirtuin activation in Caenorhabditis elegans. J
Neurosci. 2010;30:5394–403.
18. Kashyap SS, Johnson JR, McCue HV, Chen X, Edmonds MJ, Ayala M, et al.
Caenorhabditis elegans dnj-14, the orthologue of the DNAJC5 gene
mutated in adult onset neuronal ceroid lipofuscinosis, provides a new
platform for neuroprotective drug screening and identifies a SIR-2.1-
independent action of resveratrol. Hum Mol Genet. 2014;23:5916–27.
19. Noskova L, Stranecky V, Hartmannova H, Pristoupilova A, Baresova V, Ivanek
R, et al. Mutations in DNAJC5, encoding cysteine-string protein alpha, cause
autosomal-dominant adult-onset neuronal ceroid lipofuscinosis. Am J Hum
Genet. 2011;89:241–52.
20. Benitez BA, Alvarado D, Cai Y, Mayo K, Chakraverty S, Norton J, et al. Exome-
sequencing confirms DNAJC5 mutations as cause of adult neuronal ceroid-
lipofuscinosis. PLoS One. 2011;6:e26741.
21. Velinov M, Dolzhanskaya N, Gonzalez M, Powell E, Konidari I, Hulme W, et al.
Mutations in the gene DNAJC5 cause autosomal dominant Kufs disease in a
proportion of cases: study of the Parry family and 8 other families. PLoS
One. 2012;7:e29729.
22. Cadieux-Dion M, Andermann E, Lachance-Touchette P, Ansorge O, Meloche
C, Barnabe A, et al. Recurrent mutations in DNAJC5 cause autosomal
dominant Kufs disease. Clin Genet. 2013;83:571–5.
23. Zinsmaier KE, Eberle KK, Buchner E, Walter N, Benzer S. Paralysis and early death
in cysteine string protein mutants of Drosophila. Science. 1994;263:977–80.
24. Chamberlain LH, Burgoyne RD. Cysteine-string protein: the chaperone at
the synapse. J Neurochem. 2000;74:1781–9.
25. Sharma M, Burre J, Sudhof TC. CSPalpha promotes SNARE-complex
assembly by chaperoning SNAP-25 during synaptic activity. Nat Cell Biol.
2011;13:30–9.
26. Sharma M, Burre J, Sudhof TC. Proteasome inhibition alleviates SNARE-
dependent neurodegeneration. Sci Transl Med. 2012;4:147ra113.
27. Burgoyne RD, Morgan A. Chaperoning the SNAREs: a role in preventing
neurodegeneration? Nat Cell Biol. 2011;13:8–9.
28. Fernandez-Chacon R, Wolfel M, Nishimune H, Tabares L, Schmitz F,
Castellano-Munoz M, et al. The synaptic vesicle protein CSP alpha prevents
presynaptic degeneration. Neuron. 2004;42:237–51.
29. Kraemer BC, Zhang B, Leverenz JB, Thomas JH, Trojanowski JQ, Schellenberg
GD. Neurodegeneration and defective neurotransmission in a
Caenorhabditis elegans model of tauopathy. Proc Natl Acad Sci U S A.
2003;100:9980–5.
30. Crunelli V, Leresche N. Block of thalamic T-type Ca(2+) channels by
ethosuximide is not the whole story. Epilepsy Curr. 2002;2:53–6.
31. Steger KA, Shtonda BB, Thacker C, Snutch TP, Avery L. The C. elegans T-type
calcium channel CCA-1 boosts neuromuscular transmission. J Exp Biol.
2005;208:2191–203.
32. Gems D, Riddle DL. Defining wild-type life span in Caenorhabditis elegans. J
Gerontol A Biol Sci Med Sci. 2000;55:B215–9.
33. Cabreiro F, Au C, Leung KY, Vergara-Irigaray N, Cocheme HM, Noori T, et al.
Metformin retards aging in C. elegans by altering microbial folate and
methionine metabolism. Cell. 2013;153:228–39.
34. Murphy CT, McCarroll SA, Bargmann CI, Fraser A, Kamath RS, Ahringer J,
et al. Genes that act downstream of DAF-16 to influence the lifespan of
Caenorhabditis elegans. Nature. 2003;424:277–83.
35. Henderson ST, Johnson TE. Daf-16 integrates developmental and
environmental inputs to mediate aging in the nematode Caenorhabditis
elegans. Curr Biol. 2001;11:1975–80.
36. Salih DA, Brunet A. FoxO transcription factors in the maintenance of cellular
homeostasis during aging. Curr Opin Cell Biol. 2008;20:126–36.
37. Kang ML, Kwon JS, Kim MS. Induction of neuronal differentiation of rat
muscle-derived stem cells in vitro using basic fibroblast growth factor and
ethosuximide. Int J Mol Sci. 2013;14:6614–23.
38. Park SH, Kukushkin Y, Gupta R, Chen T, Konagai A, Hipp MS, et al. PolyQ
proteins interfere with nuclear degradation of cytosolic proteins by
sequestering the Sis1p chaperone. Cell. 2013;154:134–45.
39. Collins JJ, Evason K, Pickett CL, Schneider DL, Kornfeld K. The anticonvulsant
ethosuximide disrupts sensory function to extend C elegans lifespan. PLoS
Genet. 2008;4:e1000230.
40. Bargmann CI. Neurobiology of the Caenorhabditis elegans genome.
Science. 1998;282:2028–33.
41. Evason K, Huang C, Yamben I, Covey DF, Kornfeld K. Anticonvulsant
medications extend worm life-span. Science. 2005;307:258–62.
42. Choi H, Schneider H, Klum S, Chandler-Brown D, Kaeberlein M, Shamieh L.
UV-Photoconversion of ethosuximide from a longevity-promoting
compound to a potent toxin. PLoS One. 2013;8:e82543.
43. Cohen E, Bieschke J, Perciavalle RM, Kelly JW, Dillin A. Opposing activities
protect against age-onset proteotoxicity. Science. 2006;313:1604–10.
44. Zhang T, Mullane PC, Periz G, Wang J. TDP-43 neurotoxicity and protein
aggregation modulated by heat shock factor and insulin/IGF-1 signaling.
Hum Mol Genet. 2011;20:1952–65.
45. Morley JF, Brignull HR, Weyers JJ, Morimoto RI. The threshold for
polyglutamine-expansion protein aggregation and cellular toxicity is
dynamic and influenced by aging in Caenorhabditis elegans. Proc Natl Acad
Sci U S A. 2002;99:10417–22.
46. Cohen E, Paulsson JF, Blinder P, Burstyn-Cohen T, Du D, Estepa G, et al.
Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell.
2009;139:1157–69.
47. Tepper RG, Ashraf J, Kaletsky R, Kleemann G, Murphy CT, Bussemaker HJ.
PQM-1 complements DAF-16 as a key transcriptional regulator of DAF-2-
mediated development and longevity. Cell. 2013;154:676–90.
48. Kops GJ, Dansen TB, Polderman PE, Saarloos I, Wirtz KW, Coffer PJ, et al.
Forkhead transcription factor FOXO3a protects quiescent cells from
oxidative stress. Nature. 2002;419:316–21.
49. Mojsilovic-Petrovic J, Nedelsky N, Boccitto M, Mano I, Georgiades SN,
Zhou W, et al. FOXO3a is broadly neuroprotective in vitro and in vivo
against insults implicated in motor neuron diseases. J Neurosci.
2009;29:8236–47.
50. Jiang M, Wang J, Fu J, Du L, Jeong H, West T, et al. Neuroprotective role of
Sirt1 in mammalian models of Huntington’s disease through activation of
multiple Sirt1 targets. Nat Med. 2012;18:153–8.
51. Pino E, Amamoto R, Zheng L, Cacquevel M, Sarria JC, Knott GW, et al.
FOXO3 determines the accumulation of alpha-synuclein and controls the
fate of dopaminergic neurons in the substantia nigra. Hum Mol Genet.
2014;23:1435–52.
52. Goren MZ, Onat F. Ethosuximide: from bench to bedside. CNS Drug Rev.
2007;13:224–39.
53. Edmonds MJ, Morgan A. A systematic analysis of protein palmitoylation in
Caenorhabditis elegans. BMC Genomics. 2014;15:841.
54. Zhang Y, Chen D, Smith MA, Zhang B, Pan X. Selection of reliable reference
genes in Caenorhabditis elegans for analysis of nanotoxicity. PLoS One.
2012;7:e31849.
55. Benjamini Y, Hochberg Y. Controlling the false discovery rate - a practical
and powerful approach to multiple testing. J R Stat Soc Ser B-Methodol.
1995;57:289–300.
Chen et al. Molecular Neurodegeneration  (2015) 10:51 Page 14 of 14
